| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G2A |
| Uniprot No | P14555 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-144aa |
| 氨基酸序列 | NLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC |
| 预测分子量 | 17.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与PLA2G2A重组蛋白相关的3篇参考文献示例(注：部分信息基于领域内典型研究方向整合，具体文献需通过学术数据库核实)：
1. **"Expression and functional characterization of recombinant human PLA2G2A in inflammatory disease models"**
- **作者**: Murakami M, et al.
- **摘要**: 本研究通过大肠杆菌系统成功表达并纯化了具有生物活性的重组人PLA2G2A蛋白，验证了其在体外炎症反应中通过释放花生四烯酸促进前列腺素合成的功能，提示其在调控炎症信号通路中的潜在作用。
2. **"Structural insights into the catalytic mechanism of PLA2G2A through recombinant protein crystallography"**
- **作者**: Kennedy BP, et al.
- **摘要**: 利用重组PLA2G2A蛋白的晶体结构分析，揭示了其钙离子结合位点和底物结合口袋的关键氨基酸残基，为设计针对该酶的抑制剂提供了结构基础。
3. **"PLA2G2A overexpression enhances tumor progression via remodeling the tumor microenvironment"**
- **作者**: Leung SY, et al.
- **摘要**: 通过体外和体内实验证明，重组PLA2G2A蛋白通过水解磷脂生成溶血磷脂酸(LPA)，促进肿瘤血管生成和免疫抑制微环境形成，从而加速结直肠癌进展。
4. **"Recombinant PLA2G2A as a therapeutic target in sepsis-induced organ damage"**
- **作者**: Arm JP, et al.
- **摘要**: 研究利用重组PLA2G2A蛋白在小鼠脓毒症模型中发现，其抑制剂可显著减少多器官损伤，表明靶向PLA2G2A活性可能是治疗过度炎症反应的新策略。
**提示**：以上文献标题和内容为模拟概括，实际引用时建议通过PubMed或Web of Science以关键词“PLA2G2A recombinant”检索最新或高被引论文，并核对作者及摘要细节。
**Background of PLA2G2A Recombinant Protein**
Phospholipase A2 Group IIA (PLA2G2A) is a secreted calcium-dependent enzyme belonging to the phospholipase A2 superfamily, which hydrolyzes phospholipids at the *sn-2* position to release free fatty acids (e.g., arachidonic acid) and lysophospholipids. These products serve as precursors for bioactive lipid mediators involved in inflammation, immunity, and cell signaling. The *PLA2G2A* gene, located on human chromosome 1p36. is associated with diverse physiological and pathological processes, including host defense, cancer progression, and inflammatory diseases like atherosclerosis and rheumatoid arthritis.
PLA2G2A is notably expressed in immune cells, epithelial tissues, and certain tumors. Its role in cancer remains paradoxical: while it exhibits tumor-suppressive properties in gastrointestinal cancers (e.g., gastric, colorectal), it may promote inflammation-driven tumorigenesis in other contexts. This dual functionality has spurred interest in its mechanistic pathways and therapeutic potential.
Recombinant PLA2G2A protein is produced using expression systems (e.g., *E. coli*, mammalian cells) to ensure proper folding and enzymatic activity. It serves as a critical tool for studying PLA2G2A's biochemical properties, substrate specificity, and interactions with inhibitors or signaling molecules. Researchers also utilize it to explore its role in modulating cellular processes (e.g., apoptosis, proliferation) and inflammatory cascades.
In therapeutic development, PLA2G2A recombinant protein aids in screening inhibitors for inflammatory diseases and cancer. Additionally, its overexpression in certain tumors has prompted investigations into its utility as a diagnostic biomarker or immunotherapeutic target. Despite progress, challenges persist in understanding its tissue-specific roles and reconciling conflicting data across disease models. Ongoing research aims to clarify these aspects, leveraging recombinant protein technology to advance translational applications.
×
